Study to Investigate the Efficacy and Safety of Mexiletine in Patients With Myotonic Dystrophy Type 1 and Type 2

NCT04700046 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Assessing novel alternative study designs and regulatory pathways

Conditions

Myotonic Dystrophy Type 1 and Type 2

Interventions

DRUG: Mexiletine 167 mg
DRUG: Placebo

Sponsor

Lupin Ltd.